Last reviewed · How we verify

NVP-2203-R1

NVP Healthcare · Phase 3 active Small molecule

NVP-2203-R1 is a SGLT2 inhibitor Small molecule drug developed by NVP Healthcare. It is currently in Phase 3 development for Type 2 diabetes.

NVP-2203-R1 is a small molecule that targets the SGLT2 receptor.

NVP-2203-R1 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.

At a glance

Generic nameNVP-2203-R1
SponsorNVP Healthcare
Drug classSGLT2 inhibitor
TargetSGLT2
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

By inhibiting SGLT2, NVP-2203-R1 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly effective in treating type 2 diabetes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about NVP-2203-R1

What is NVP-2203-R1?

NVP-2203-R1 is a SGLT2 inhibitor drug developed by NVP Healthcare, indicated for Type 2 diabetes.

How does NVP-2203-R1 work?

NVP-2203-R1 is a small molecule that targets the SGLT2 receptor.

What is NVP-2203-R1 used for?

NVP-2203-R1 is indicated for Type 2 diabetes.

Who makes NVP-2203-R1?

NVP-2203-R1 is developed by NVP Healthcare (see full NVP Healthcare pipeline at /company/nvp-healthcare).

What drug class is NVP-2203-R1 in?

NVP-2203-R1 belongs to the SGLT2 inhibitor class. See all SGLT2 inhibitor drugs at /class/sglt2-inhibitor.

What development phase is NVP-2203-R1 in?

NVP-2203-R1 is in Phase 3.

What are the side effects of NVP-2203-R1?

Common side effects of NVP-2203-R1 include Increased risk of genital yeast infections, Increased risk of ketoacidosis.

What does NVP-2203-R1 target?

NVP-2203-R1 targets SGLT2 and is a SGLT2 inhibitor.

Related